[1] 唐文军,朱益平,吴跃文,等. 唑来膦酸联合化疗治疗31例肿瘤骨转移性疼痛[J]. 皖南医学院学报,2010,(6):417-419. [2] Alegre A,Gironella M,Bailen A,et al.Zoledronic acid in the management of bone disease as a consequence of multiple myeloma:a review[J]. Eur J Haemato,2014,92(3):181-188. [3] Reid I R,Gamble G D,Mesenbrink P,et al.Characterization of and risk factors for the acute-phase response after zoledronic acid[J]. J Clin Endocrinol Metab,2010,95(9):4380-4387. [4] 车建华,杨保庆,杨玲玲,等. 希罗达联合唑来膦酸治疗乳腺癌多发骨转移疗效观察[J]. 实用医学杂志,2012,28(6):979-981. [5] 叶文成,李莹,张波.双膦酸盐相关性颌骨坏死1例报告及文献复习[J]. 上海口腔医学, 2012, 21(3):354-358. [6] 章斌, 田泾, 金剑. 唑来膦酸致多发性骨髓瘤患者下颌骨坏死1例报告与分析[J]. 上海医药, 2017, 38(19):3-5. [7] 陈菊仙, 郭雪华, 阮宏, 等. 唑来膦酸并发的上颌骨坏死2例报告[J]. 口腔颌面外科杂志, 2012, 22(5):378-380. [8] 盛璐, 文建民, 童昕. 双磷酸盐相关性颌骨坏死1例报道及文献复习[J]. 广东牙病防治,2013, 21(12):660-662. [9] 秦铁军, 杨舟, 徐泽锋, 等. 唑来膦酸钠致多发性骨髓瘤患者下颌骨坏死一例[J]. 中华血液学杂志, 2008, 29(10):714. [10] 刁晓洁, 张立平, 英杰, 等. 双磷酸盐相关上颌骨坏死:一例报道并文献复习[J]. 新疆医学, 2014, 44(9):116-118. [11] 王琴, 秦燕, 孙燕, 等. 唑来膦酸治疗膀胱癌骨转移致上颌骨坏死一例. 中华医学杂志, 2016, 96(16):1303-1303. [12] 李冉, 李宁. 唑来膦酸相关下颌骨骨坏死病例报告1例及文献复习[J]. 西南军医,2012, 14(6):921-922 [13] 刘燕. 唑来膦酸致骨髓炎4例[J]. 临床合理用药杂志, 2018, 11(7):39,42. [14] 戴月华, 张海军. 唑来膦酸加速肾功能损害引起死亡1例[J]. 中国药师,2006,9(9):814 [15] 贾晓峰, 刘莹莹. 唑来膦酸致下颌骨疼痛一例[J]. 山西医药杂志, 2014, 43(7):845-845. [16] 张改英, 李晓彦, 刘永兰, 等. 唑来膦酸注射液治疗骨继发性恶性肿瘤致高热1例[J]. 中国保健营养, 2018, 28(11):290. [17] 肖玉芹, 李莉. 唑来膦酸致高热1例[J]. 当代临床医刊, 2015, 28(5):1682-1683. [18] 吴东媛, 关尚为, 刘铎, 等. 唑来膦酸致严重骨痛1例[C]//2014年中国临床药学学术年会暨第十届中国临床药师论坛论文集. 2014:130-133. [19] 曹斌, 曹国文, 潘杰. 临床药师参与唑来膦酸致全血细胞减少的会诊病例分析[J]. 药物资讯, 2018, 7(3):52-56. [20] 曹永红. 唑来膦酸钠注射剂致低钙血症2例[J]. 中国药师, 2007, 10(4):372. [21] 王颖轶, 管梅, 白春梅, 等. 唑来膦酸钠静脉注射导致低钙血症一例[J]. 中国肿瘤临床与康复, 2013, 20(12):1429-1430. [22] 曾俊权, 刘彬, 方木水. 唑来膦酸治疗肺癌骨转移出现全身皮疹的个案报告[J]. 赣南医学院学报, 2016, 36(3):431,433. [23] 张梁. 唑来膦酸致患者过度兴奋1例[J]. 中南药学, 2018,16(10):1500-1501. [24] 吴学勇, 朱悦茗, 谢芳. 唑来膦酸治疗骨质疏松致严重皮疹一例[J]. 中国肿瘤临床与康复, 2015, 22(12):1527. [25] 杨麟. 静脉给双膦酸盐类药物出现严重低钙血症[J]. 中国处方药,2004,29(8):78-80 [26] Ristow O, GerngroβC, Schwaiger M, et al. Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?[J]. Journal of Oral & Maxillofacial Surgery, 2014, 72(5):903-910. [27] Patel V,Mcleod N M,Rogers S N,et al.Bisphosphonate osteonecrosis of the jaw-a literature of UK policies versus interational policies on bisphosphonates,risk factors and precention[J]. Br J Oral Maxillofac Sufg,2011,49(4):251-257. [28] Hoff A O,Toth B B,Altundag K,et al.Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates[J]. J Bone Miner Res,2008,23(6):826-836. [29] Hoefert S,Schmitz I, Tannapfel A,et al.Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw:a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings[J]. Clin Oral Invertig,2010,14(3):271-284. [30] Allen M R,Burr D B.The pathogenesis of bisphosphonate-related osteonecrosis of the jaw:so many hypotheses,so few data[J]. J Oral Maxillofac Surg,2009,67(5 Suppl):61-70. [31] Orwoll E,Blank J B,Barret T - Connor E,et al. Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study-a large observational study of the determinants of fracture in older men[J]. Contemp Clin Trials,2005,26(5):569-585. [32] Berenson J,Hirschberg R.Safety and convenience of a 15-minute infusion of zoledronic acid[J]. Oncologist,2009,9(3):319-329. [33] Dicuonzo G,Vincenzi B,Santini D,et al.Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6[J]. J Interferon Cytokine Res,2003,23(11):649-654. [34] 李妹英,柴华,甘海洁,等. 89SrCl2联合唑来膦酸治疗骨转移瘤的临床护理[J]. 大家健康(上旬版),2017,(12):238-239. [35] 陆琳松,旭合热提·吾提库尔,哈巴西·卡肯,等. 唑来膦酸对维吾尔族绝经后妇女骨质疏松性骨折骨代谢指标的影响[J]. 中国骨科临床与基础研究杂志,2013,5(3):138-142. [36] 黄红霞. 唑来膦酸治疗恶性肿瘤骨转移不良反应护理体会[J]. 中国现代医药杂志,2013(5):104-105. [37] 王芳芳,陈维红. 我院417例ADR报告分析[J]. 中国药房,2015,26(8):1093-1095. |